- Home
- EIC vs CYRX Comparison
EIC vs CYRX Comparison
Compare EIC & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- CYRX
- Stock Information
- Founded
- EIC N/A
- CYRX 1999
- Country
- EIC United States
- CYRX United States
- Employees
- EIC N/A
- CYRX N/A
- Industry
- EIC Finance/Investors Services
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- CYRX Health Care
- Exchange
- EIC Nasdaq
- CYRX Nasdaq
- Market Cap
- EIC 287.1M
- CYRX 310.4M
- IPO Year
- EIC 2019
- CYRX N/A
- Fundamental
- Price
- EIC $14.98
- CYRX $6.37
- Analyst Decision
- EIC Strong Buy
- CYRX Strong Buy
- Analyst Count
- EIC 1
- CYRX 6
- Target Price
- EIC $17.50
- CYRX $11.33
- AVG Volume (30 Days)
- EIC 280.3K
- CYRX 649.7K
- Earning Date
- EIC 05-20-2025
- CYRX 03-04-2025
- Dividend Yield
- EIC 16.06%
- CYRX N/A
- EPS Growth
- EIC N/A
- CYRX N/A
- EPS
- EIC 1.97
- CYRX N/A
- Revenue
- EIC $46,223,036.00
- CYRX $228,385,000.00
- Revenue This Year
- EIC $39.61
- CYRX $9.18
- Revenue Next Year
- EIC $27.28
- CYRX $8.65
- P/E Ratio
- EIC $7.60
- CYRX N/A
- Revenue Growth
- EIC 72.79
- CYRX N/A
- 52 Week Low
- EIC $14.51
- CYRX $4.58
- 52 Week High
- EIC $16.75
- CYRX $20.11
- Technical
- Relative Strength Index (RSI)
- EIC 38.67
- CYRX 54.54
- Support Level
- EIC $14.81
- CYRX $5.90
- Resistance Level
- EIC $15.15
- CYRX $6.60
- Average True Range (ATR)
- EIC 0.25
- CYRX 0.61
- MACD
- EIC -0.01
- CYRX 0.09
- Stochastic Oscillator
- EIC 40.34
- CYRX 81.47
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.